

## **Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year**

Tokyo, September 18, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index, the Asia Pacific version of the Dow Jones Sustainability Indices (“DJSI”) and one of the world’s premier indices for Socially Responsible Investment (“SRI”).

The DJSI, launched jointly by Dow Jones & Company of the United States and RobecoSAM AG of Switzerland, is a leading SRI index which assesses and selects leading sustainability-driven companies in terms of economic, environmental, and social criteria.

Specifically designed for companies in the developed Asia Pacific markets including Japan, the Dow Jones Sustainability Asia Pacific Index has selected 145 companies, including 62 Japanese companies, which are leading the way in terms of sustainability among 600 companies in the region.

Through a wide range of CSR activities, Astellas will continue to strive to create and protect social value, contribute to the sustainable development of society and consequently enhance its enterprise value.

### **About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>